Skip to main
NRIX

NRIX Stock Forecast & Price Target

NRIX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nurix Therapeutics is expected to have a positive outlook due to its strong pipeline of drug candidates targeting specific proteins involved in immune and cancer-related pathways, as well as its integrated discovery platform that incorporates artificial intelligence and ligase expertise. The company's partnership collaborations with Pfizer (Seagen), Gilead, and Sanofi also provide additional support and resources for its research and development efforts. Although risks exist such as negative clinical trial results or failure to obtain timely approvals, Nurix's ongoing clinical trials and upcoming catalysts provide potential for growth and future success.

Bears say

Nurix Therapeutics is a clinical-stage biopharmaceutical company with a strong pipeline of targeted protein degradation therapies for cancer and inflammatory diseases. Despite showcasing promising preclinical data for several of its drug candidates, the company faces competition from other biopharmaceutical companies with similar technologies, potentially limiting its market share. Furthermore, the success of these treatments is dependent on obtaining timely approval and gaining market acceptance, which may not be guaranteed. Additionally, the recent rise in interest in the DAC modality proves the potential of novel treatments, but Nurix will face significant risks, such as clinical failure or lack of partnership opportunities, in bringing these therapies to market. Overall, this raises concerns about the company's ability to generate significant revenue in the near future.

NRIX has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nurix Therapeutics, Inc (NRIX) Forecast

Analysts have given NRIX a Buy based on their latest research and market trends.

According to 13 analysts, NRIX has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nurix Therapeutics, Inc (NRIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.